News

  • Active Care Group joins Onward

    ACG named as care partner for the patient support service, which works with patients and families in hospital settings

  • On the trail of rehab funding foes and threats

    Financial compensation is intended to help brain injury survivors manage their condition for the rest of their lives. But what happens when the money is lost through mismanagement, fraud or exploitation?

    NR Times spoke to Liesel Annible - a forensic director at accountancy, financial and business advisory firm Armstrong Watson, to find out more about the financial investigation process.
  • Above and Beyond finalists revealed

    The latest shortlist in the NR Times Awards has been unveiled, ahead of the awards ceremony next week

  • Global brain disease patient population expected to double by 2050

    The number of people with neurological disorders globally is on track to double by 2050, new data suggests.

    Neurological conditions are currently the second highest cause of death and the leading cause of disability worldwide and a new Global Burden of Disease (GBD) study suggests their impact could accelerate further in coming decades.
  • Charity of the Year shortlist revealed

    The ten finalists have been announced ahead of next week's awards ceremony

  • Augmented reality device maker aims to transform neuro-rehab

    A device which harnesses augmented reality (AR) to address gait and balance motor issues in Parkinson’s patients could be expanded to also help stroke survivors and people living with MS; following an investment boost.

  • WHO calls for urgent action on addressing neurological disorders

    World Health Organisation presents international blueprint which it hopes will impact on the lives of people with neurological disorders. 

    The World Health Organisation (WHO) has called for urgent action from governments and healthcare organisations around the world to help address and better manage neurological conditions.
  • Expert analysis: New dimensions in our understanding of MS

    By Norman Putzki (MD PhD), global head development neuroscience and gene therapy at Novartis.

    Over the last 30 years, remarkable progress has been made in the advancement of treating multiple sclerosis (MS), a potentially disabling disease that is most likely a consequence of complex autoimmune dysfunctions in the periphery ultimately leading to demyelination in the central nervous system (CNS).

    Since 1993, a series of insights has led to greater understanding of the biological mechanisms and triggers driving the inflammatory attacks on the CNS.

    These translational insights have also driven the development of newer and more effective treatments in MS.

  • Six shortlisted for Remote Rehab Initiative of the Year

    Finalists revealed in the inaugural NR Times Awards, with awards ceremony set for next week

  • ‘Stark’ findings reveal scale of brain injury among domestic abuse survivors

    Up to one in two survivors of domestic abuse in the UK may be living with an undiagnosed brain injury, according to new research from Brainkind.

    A new study conducted by Brainkind aims to shine a light on the prevalence of unrecognised brain injuries among domestic abuse survivors in the UK. In a new paper due to be published this month...